- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01372566
Effect of Platelet Rich Plasma on Photoaged Skin
March 14, 2024 updated by: Murad Alam, Northwestern University
Effect of Autologous Platelet-rich Plasma on Photoaged Skin: A Prospective Randomized Controlled Trial (Phases A and B)
The goal of this study is to assess the safety, tolerability and effectiveness of platelet rich plasma in the treatment of photoaged skin.
This study will be divided into two parts.
The first part will assess the safety and tolerability of platelet rich plasma injections as compared to sterile saline injections in subjects' arm with six months follow-up.
The second part will assess the effect of platelet rich plasma on the appearance of facial skin in a split face study with platelet rich plasma injections on one side of the face and sterile saline on the other.
Outcomes will be recorded for twelve months.
Study Overview
Status
Active, not recruiting
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Estimated)
23
Phase
- Phase 2
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Illinois
-
Chicago, Illinois, United States, 60611
- Northwestern University Dermatology
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
35 years to 60 years (Adult)
Accepts Healthy Volunteers
Yes
Description
Inclusion Criteria:
Part 1:
- Subjects of either gender (M/F), 35-60 years old.
- Subjects are in good health.
- Subjects who are willing and have the ability to understand and provide informed consent for participation in the study and are able to communicate with the investigator.
Part 2:
- Subjects of either gender (M/F), 35-60 years old.
- Subjects are in good health.
- Bilateral cheek wrinkles "in motion" with severities of ≥ type II of Glogau photoaging classification (APPENDIX I).
- Subjects who are willing and have the ability to understand and provide informed consent for participation in the study and are able to communicate with the investigator.
- Subject requests cosmetic improvement of facial wrinkles.
Exclusion Criteria:
- Pregnant or lactating.
- Subjects who are unable to understand the protocol or to give informed consent.
- Subjects who have a self-reported history of blood or platelet disorders e.g. anemia, thrombocytopenia, coagulopathy, hypofibrinogenemia, or are on anticoagulant or antiplatelet therapy.
- Subjects who have active skin disease or skin infection in treatment area. Subjects who have a history of hypertrophic scars and keloids.
- Subjects who have any requirement for the use of local or systemic steroids or immunosuppressive agents.
- Subject notes that he/she is HIV positive
- Subjects with history of skin cancer or actinic keratosis
- Uncooperative patients or patients with neurological disorders who are incapable of following directions or who are predictably unwilling to return for follow-up examinations.
- Skin conditions that interfere with wrinkle assessment/treatment (excessive dermatochalasis, inability to lessen the wrinkles by physically spreading the area apart).
- Excessive exposure to the sun, such as jobs requiring constant outdoor exposure.
- Known genetic disorders affecting fibroblasts or collagen, such as achondroplasia, osteogenesis imperfecta, ect.
Part 2:
- Pregnant or lactating.
- Subjects who are unable to understand the protocol or to give informed consent.
- Subjects who have a history of blood or platelet disorders e.g. anemia, thrombocytopenia, coagulopathy, hypofibrinogenemia, or are on anticoagulant or anti-platelet therapy.
- Subjects who have had topical or oral tretinoin, chemical peeling, botulinum toxin injection or laser and light treatment for facial rhytides or rejuvenation within past 6 months or planning to undergo treatments as described in the next 3 months.
- Facial surgery in the lower 2/3 of the face or semi-permanent dermal fillers within 1 year prior to study enrollment
- Subjects who have history of recurrent facial or labial herpes simplex infection.
- Subjects who have active skin disease or skin infection in treatment area.
- Subjects who are allergic to lidocaine or prilocaine.
- Subjects who have a history of hypertrophic scars and keloids.
- Subjects who have any requirement for the use of local or systemic steroids or immunosuppressive agents.
- Subject notes that he/she is HIV positive
- Subjects with history of skin cancer or actinic keratosis
- Uncooperative patients or patients with neurological disorders who are incapable of following directions or who are predictably unwilling to return for follow-up examinations.
- Skin conditions that interfere with wrinkle assessment/treatment (excessive dermatochalasis, inability to lessen the wrinkles by physically spreading the area apart).
- Excessive exposure to the sun, such as jobs requiring constant outdoor exposure.
- Known genetic disorders affecting fibroblasts or collagen, such as achondroplasia, osteogenesis imperfecta, ect.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Single Group Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Platelet Rich Plasma
Concentrated blood platelets from subject will be injected multiple times into the superficial layer of either their arm (Part 1) or one side of their upper face and cheek (Part 2).
|
Platelet-rich plasma (PRP) is a blood-derived therapy that consists of platelets and growth factors.
PRP can be formed by drawing blood from a vein and spinning it at a high speed in a specialized device called a centrifuge.
|
Placebo Comparator: Sterile Saline
Sterile saline will be injected multiple times into the superficial layer of either their arm (Part 1) or one side of their upper face and cheek (Part 2)that has not been injected with PRP.
|
Sterile Saline will be injected multiple times in a different area of the arm (Part 1) or on the opposite side of the face from where the platelet rich plasma is injected.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Primary Outcome Study Part 1: Safety and Tolerability
Time Frame: 2 weeks, 1 month, 3 months and 6 months
|
The primary outcome measures will be the evaluation of safety and tolerability, which will be assessed by collection of adverse events throughout the feasibility study.
|
2 weeks, 1 month, 3 months and 6 months
|
Primary Outcome Study Part 2: Change in Photoaging scores from Baseline at 2 weeks, 3 months, and 6 months
Time Frame: Treatment visit, 2 weeks, 3 months and 6 months
|
Photoaging scores will be recorded for each cheek by two blinded dermatologists at the treatment visit (before treatment)and during the 2 week, 3 month, and 6 month post-treatment visits.
Individual scores for each variable (fine lines, mottled pigmentation, roughness, and sallowness) will be recorded by the blinded dermatologists.
|
Treatment visit, 2 weeks, 3 months and 6 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Secondary Outcome of Study Part 1: Histologic analysis
Time Frame: 1 month
|
The secondary outcomes measures will involve the dermatopathologic review of the 2 skin biopsies taken from each subject at the one month post-treatment visit.
One 3mm biopsy will be taken from the skin where the saline was injected and the other from the site of PRP injection.
These will be reviewed by the dermatopathologists in the Department of Dermatology for significant histological changes, including collagen remodeling and possible reduction in photodamage.
Histologic stains will include hematoxylin and eosin and Masson's trichrome.
|
1 month
|
Secondary Outcome Study Part 2: Self-Assessment
Time Frame: 3 and 6 months
|
A subject self-assessment of each cheek will be performed at the 3 and 6 month follow up visits.
|
3 and 6 months
|
Secondary Outcome Study Part 2: Subject Satisfaction
Time Frame: 6 months
|
A subject overall satisfaction questionnaire will be performed at the 6 month follow up visit.
|
6 months
|
Secondary Outcome Study Part 2: Rate of Adverse Events
Time Frame: 2 weeks, 3 months, 6 months, 12 months
|
Adverse events will be recorded at each time point, if they occur.
Statitical analysis will determine the rate of any adverse events between PRP and Saline.
|
2 weeks, 3 months, 6 months, 12 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Murad Alam, MD, Northwestern University
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
May 1, 2011
Primary Completion (Estimated)
December 1, 2025
Study Completion (Estimated)
December 1, 2025
Study Registration Dates
First Submitted
June 1, 2011
First Submitted That Met QC Criteria
June 10, 2011
First Posted (Estimated)
June 14, 2011
Study Record Updates
Last Update Posted (Actual)
March 18, 2024
Last Update Submitted That Met QC Criteria
March 14, 2024
Last Verified
March 1, 2024
More Information
Terms related to this study
Other Study ID Numbers
- STU34547
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Photoaging
-
Dr.dr.Irma Bernadette, SpKK (K)Not yet recruiting
-
University of ManchesterUnknownPhotoagingUnited Kingdom
-
Integrative Skin Science and ResearchSytheon Ltd.Not yet recruitingThe Effects of Zinc Di-(Dibutyryl Lisinate) on Skin Health and the Skin Microbiome in Photoaged SkinPhotoagingUnited States
-
Universitätsklinikum Hamburg-EppendorfNot yet recruiting
-
Integrative Skin Science and ResearchNational Mango BoardNot yet recruiting
-
Bausch Health Americas, Inc.Completed
-
Galderma R&DCompletedPhotoagingUnited States
-
Derming SRLCompleted
-
Revision SkincareKGL, Inc.CompletedWrinkle | PhotoagingUnited States
-
University of California, DavisCompleted
Clinical Trials on Harvest PRP Separation System
-
University of ArizonaTerminatedSkin Graft Complications | PRP | Skin Graft (Allograft) Rejection | Skin Graft DetachmentUnited States
-
Harvest TechnologiesTerminated
-
Restoration Robotics, Inc.Completed
-
Harvest TechnologiesCompleted
-
Loma Linda UniversityCompletedAnxiety, SeparationUnited States
-
National Heart, Lung, and Blood Institute (NHLBI)Children's Hospital Medical Center, CincinnatiCompletedFanconi AnemiaUnited States
-
CHU de ReimsEtablissement Français du SangCompleted
-
University of California, DavisRecruitingHead and Neck Cancer | Surgery--Complications | Graft FailureUnited States
-
Memorial Sloan Kettering Cancer CenterActive, not recruitingAlopeciaUnited States
-
Krishnadevaraya College of Dental Sciences & HospitalUnknownWound Healing